Jazz Pharmaceuticals price target raised to $70 from $63 at WallachBeth WallachBeth raised its price target for Jazz Pharmaceuticals following the company's better than expected Q4 results and reiterates a Buy rating on the stock. The firm believes Jazz's outlook leaves room for upside.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Allergan merger deal not imminent, CNBC's Faber reports An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.